Consequently, adoption lag times for important new treatments have become unacceptable
1 (2023): 69, 10.1186/s12933-023-01800-z
What the Evidence Does NOT Show It is worth being blunt and specific about the claims these blends cannot support, because the gap between what is marketed and what is known is where people get misled
Questions remain about the safety of these drugs with regard to the risk of pancreatitis and the development of MTC in patients receiving liraglutide
DaVita disclaims any obligation to update or revise any forward-looking statement contained in this press release, whether as a result of changed circumstances, new information, future events or otherwise, except as may be otherwise required by law
Altered glucose metabolism after bariatric surgery: what's GLP-1 got to do with it